FIG. 7.

Ola treatments inhibit JNK1/2‐ph‐S6‐p53 pathway and reduce expression of ph‐S6‐p53‐PARP1‐dependent, ALCD‐containing genes. (A) Treatments of Huh6 cells with Ola inhibit the JNK1/2‐ph‐S6‐p53 pathway. (B) ChIP assay with ALCDs in NRF2 and beta‐catenin genes. (C) JNK1/2‐ph‐S6‐p53 pathway is activated in patients with aggressive HBL (upper) and HCC (bottom). WB was performed with background and tumor sections of patients with HBL and HCC. (D) Left: WB shows that the inhibition of JNK1/2 reduces levels of ph‐S6‐p53 protein. Right: Co‐IP studies. (E) Levels of ALCD‐dependent proteins are reduced in Huh6 cells with inhibited JNK1/2. WB was performed with Abs shown on the right. (F) Levels of ALCD‐dependent proteins are reduced in HepG2 cells treated with inhibitor of JNK1/2 SP600125.